FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

Summary

The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.

Timeline

Start

2026-07

Primary completion

2027-09

Completion

2027-09

Drugs

Indications